nicotine has been researched along with carbamazepine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Miller, M; Moses, AM | 1 |
| Karmen, A; Lehrer, M | 1 |
| Chow, SC; Johnston, GA; Skerritt, JH | 1 |
| Bertrand, D; Hogg, RC | 1 |
| Ambrosi, P; Becchetti, A; Curia, G; Di Resta, C | 1 |
| Benowitz, NL; Gandhi, KK; Williams, JM | 1 |
| Desaer, C; Ramakrishnan, L | 1 |
| Green, MD; Helmy, R; Regalado, EL; Welch, CJ | 1 |
| Abe, K; Hashimura, M; Iha, HA; Iwai, C; Kato, M; Kawaji, S; Kawakita, K; Kunisawa, N; Ogawa, M; Ohno, Y; Shimizu, S | 1 |
| Ekpeghere, KI; Lee, HJ; Oh, JE; Sim, WJ | 1 |
1 review(s) available for nicotine and carbamazepine
| Article | Year |
|---|---|
Neuronal nicotinic receptors and epilepsy, from genes to possible therapeutic compounds.
Topics: Animals; Carbamazepine; Epilepsy, Frontal Lobe; Gene Expression; Humans; Ligands; Models, Biological; Mutation; Neurons; Nicotine; Receptors, Nicotinic | 2004 |
21 other study(ies) available for nicotine and carbamazepine
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Drug-induced stated of impaired water excretion.
Topics: Analgesics; Antidepressive Agents, Tricyclic; Antineoplastic Agents; Arginine Vasopressin; Biguanides; Carbamazepine; Clofibrate; Diuretics; Humans; Kidney; Narcotics; Nicotine; Sulfonylurea Compounds; Vasopressins; Water-Electrolyte Balance; Water-Electrolyte Imbalance | 1976 |
Chemical ionization mass spectrometry for rapid assay of drugs in serum.
Topics: Anticonvulsants; Barbiturates; Caffeine; Carbamazepine; Electrochemistry; Mass Spectrometry; Nicotine; Phenytoin; Primidone; Temperature; Time Factors | 1976 |
Interactions of the anticonvulsant carbamazepine with adenosine receptors. 2. Pharmacological studies.
Topics: Animals; Carbamazepine; Guinea Pigs; Ileum; Male; Mice; Mice, Inbred Strains; Nicotine; Purines; Receptors, Cell Surface; Receptors, Purinergic; Seizures; Theophylline | 1983 |
Effect of carbamazepine and oxcarbazepine on wild-type and mutant neuronal nicotinic acetylcholine receptors linked to nocturnal frontal lobe epilepsy.
Topics: Action Potentials; Anticonvulsants; Carbamazepine; Cell Line; Epilepsy, Frontal Lobe; Humans; Molecular Structure; Mutation; Nicotine; Patch-Clamp Techniques; Protein Binding; Protein Subunits; Receptors, Nicotinic; Transfection | 2010 |
Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness.
Topics: Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Bipolar Disorder; Carbamazepine; Cotinine; Cytochrome P-450 CYP2A6; Enzyme Induction; Female; Humans; Male; Middle Aged; Nicotine; Oxcarbazepine; Schizophrenia; Smoking; Valproic Acid; Young Adult | 2010 |
Carbamazepine inhibits distinct chemoconvulsant-induced seizure-like activity in Dugesia tigrina.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Convulsants; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; GABA Antagonists; N-Methylaspartate; Nicotine; Nicotinic Agonists; Oxcarbazepine; Picrotoxin; Planarians; Seizures; Structure-Activity Relationship | 2011 |
Chromatographic resolution of closely related species: drug metabolites and analogs.
Topics: Carbamazepine; Chromatography, High Pressure Liquid; Chromatography, Supercritical Fluid; Gonadal Steroid Hormones; Molecular Structure; Morphine Derivatives; Nicotine; Xanthine | 2014 |
Pharmacological characterization of nicotine-induced tremor: Responses to anti-tremor and anti-epileptic agents.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Benzeneacetamides; Calcium Channel Blockers; Carbamazepine; Diazepam; Disease Models, Animal; Essential Tremor; Ethosuximide; Male; Mice, Inbred Strains; Nicotine; Phenobarbital; Propranolol; Pyridines; Valproic Acid | 2018 |
Occurrence and distribution of carbamazepine, nicotine, estrogenic compounds, and their transformation products in wastewater from various treatment plants and the aquatic environment.
Topics: Carbamazepine; Environmental Monitoring; Estrogens; Humans; Nicotine; Pharmaceutical Preparations; Sewage; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2018 |